Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 0.85 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.85 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.81 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.81 |
| ▸ | USP7 | Q93009 | 2/20 | 0.81 |
| ▸ | USP2 | O75604 | 1/20 | 0.81 |
| ▸ | STAT3 | P40763 | 1/20 | 0.81 |
| ▸ | CCR6 | P51684 | 1/20 | 0.73 |
| ▸ | RORC | P51449 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27366678 | 1.00 | NOS2 (0.85) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL17553223 | 1.00 | NOS2 (0.85) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL22964810 | 1.00 | NOS2 (0.85) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL30988442 | 1.00 | NOS2 (0.85) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL18973358 | 1.00 | NOS2 (0.85) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL24337284 | 0.92 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL954253 | 0.92 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL19236126 | 0.92 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL92342 | 0.92 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL18572801 | 0.92 | CYP3A4 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137947-A1 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210040142-A1 | C17 POLAR-SUBSTITUTED HETEROAROMATIC SYNTHETIC TRITERPENOIDS AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2021-02-11 | — | — | US | disclosed |
| US-20200129530-A1 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2020-04-30 | — | — | US | disclosed |
| US-10398711-B2 | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof | REATA PHARMACEUTICALS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3492077-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | Reata Pharmaceuticals, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-2252283-B9 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS INC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20180161311-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-9889143-B2 | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof | REATA PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170165278-A1 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-9512094-B2 | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof | REATA PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150225352-A1 | CDDO-ME AMINO ACID CONJUGATES AND METHODS OF USE | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150152071-A1 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20140088163-A1 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2013074556-A1 | METHODS OF INDUCING CHONDROGENESIS IN MESENCHYMAL STEM CELLS USING SYNTHETIC TRITERPENOIDS | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2013-05-23 | — | — | WO | disclosed |
| US-8129429-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | REATA PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| WO-2009089545-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009023845-A2 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20090048205-A1 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2009-02-19 | — | — | US | disclosed |
| WO-2008136838-A1 | NOVEL AMIDE DERIVATIVES OF CDDO AND METHODS OF USE THEREOF | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152071-A1 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | CYP46A1, CYP11B1, ALOX12 | NOS2 534/4885KEAP1 170/4885CYP3A4 105/4885 |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | NOS2 378/4885KEAP1 444/4885CYP3A4 752/4885 |
| US-20180161311-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | NOS2 378/4885KEAP1 444/4885CYP3A4 752/4885 |
| US-20090048205-A1 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | RABGGTB, BAD, PGGT1B | NOS2 3154/4885KEAP1 1567/4885CYP3A4 1771/4885 |
| US-20150225352-A1 | CDDO-ME AMINO ACID CONJUGATES AND METHODS OF USE | DAO, DDO, HAAO | NOS2 113/4885KEAP1 622/4885CYP3A4 1948/4885 |
| US-20210137947-A1 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | CYP46A1, CYP11B1, ALOX12 | NOS2 534/4885KEAP1 170/4885CYP3A4 105/4885 |
| US-20170165278-A1 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | CYP46A1, CYP11B1, ALOX12 | NOS2 534/4885KEAP1 170/4885CYP3A4 105/4885 |
| US-20200129530-A1 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | CYP46A1, CYP11B1, ALOX12 | NOS2 534/4885KEAP1 170/4885CYP3A4 105/4885 |
| US-20140088163-A1 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | CYP46A1, CYP11B1, ALOX12 | NOS2 534/4885KEAP1 170/4885CYP3A4 105/4885 |
| US-10398711-B2 | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof | CYP46A1, CYP11B1, ALOX12 | NOS2 534/4885KEAP1 170/4885CYP3A4 105/4885 |
| US-20210040142-A1 | C17 POLAR-SUBSTITUTED HETEROAROMATIC SYNTHETIC TRITERPENOIDS AND METHODS OF USE THEREOF | CYP11B1, CYP11B2, RORC | NOS2 1277/4885KEAP1 172/4885CYP3A4 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.